Overview
- Dupixent revenue rose 26% to about €4.2 billion (roughly $4.9 billion), topping forecasts and crossing the €4 billion mark for the first time.
- Vaccine sales fell 7.8% to €3.4 billion on softer early-season flu uptake in the U.S. and price pressure, particularly in Germany.
- Total results beat expectations, with sales growing 7% in constant currency and adjusted earnings per share up more than 13%.
- Sanofi reaffirmed its outlook for high single-digit constant-currency sales growth and double-digit earnings growth for the year.
- Executives said U.S. drug-pricing talks are ongoing, while the company raised R&D spending, closed the $470 million Vigil Neuroscience deal, and reported a failure for the oral RA candidate balinatunfib.